[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE453639T1 - Phenylsubstituierte pyrimidinverbindungen zur verwendung als kinasehemmer - Google Patents

Phenylsubstituierte pyrimidinverbindungen zur verwendung als kinasehemmer

Info

Publication number
ATE453639T1
ATE453639T1 AT06734200T AT06734200T ATE453639T1 AT E453639 T1 ATE453639 T1 AT E453639T1 AT 06734200 T AT06734200 T AT 06734200T AT 06734200 T AT06734200 T AT 06734200T AT E453639 T1 ATE453639 T1 AT E453639T1
Authority
AT
Austria
Prior art keywords
kinase inhibitors
phenyl substituted
pyrimidine compounds
substituted pyrimidine
kinase
Prior art date
Application number
AT06734200T
Other languages
English (en)
Inventor
Stephen Wrobelski
Shuqun Lin
Katerina Leftheris
Liqi He
Steven Seitz
Tai-An Lin
Wayne Vaccaro
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE453639T1 publication Critical patent/ATE453639T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT06734200T 2005-02-04 2006-02-02 Phenylsubstituierte pyrimidinverbindungen zur verwendung als kinasehemmer ATE453639T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65007705P 2005-02-04 2005-02-04
US11/344,881 US20060178388A1 (en) 2005-02-04 2006-02-01 Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
PCT/US2006/003659 WO2006084017A2 (en) 2005-02-04 2006-02-02 Phenyl-substituted pyrimidine compounds useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE453639T1 true ATE453639T1 (de) 2010-01-15

Family

ID=36481437

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06734200T ATE453639T1 (de) 2005-02-04 2006-02-02 Phenylsubstituierte pyrimidinverbindungen zur verwendung als kinasehemmer

Country Status (7)

Country Link
US (2) US20060178388A1 (de)
EP (1) EP1848714B1 (de)
JP (1) JP4906738B2 (de)
AT (1) ATE453639T1 (de)
DE (1) DE602006011434D1 (de)
ES (1) ES2336025T3 (de)
WO (1) WO2006084017A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
DE102005048072A1 (de) * 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
MY149143A (en) * 2006-01-18 2013-07-15 Amgen Inc Thiazole compounds as protien kinase b (pkb) inhibitors
US20080242694A1 (en) * 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
US7919504B2 (en) * 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
EP2597098A1 (de) 2007-08-08 2013-05-29 Lexicon Pharmaceuticals, Inc. (7H-Pyrrolo-[2, 3-D]-pyrimidin-4-yl)-Piperazine als Kinasehemmer zur Behandlung von Krebs und Entzündungen
AU2008333929A1 (en) * 2007-12-03 2009-06-11 Signum Biosciences, Inc. Acid mimic compounds for the inhibition of isoprenyl-S-cysteinyl methyltransferase
WO2009093981A1 (en) * 2008-01-23 2009-07-30 S Bio Pte Ltd Triazine compounds as kinase inhibitors
WO2009096198A1 (ja) * 2008-02-01 2009-08-06 Pharma Ip Limited Liability Intermediary Corporations 新規ビアリール誘導体
WO2009125870A1 (en) 2008-04-09 2009-10-15 Mitsubishi Tanabe Pharma Corporation Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers.
KR20160129909A (ko) 2008-04-21 2016-11-09 렉시컨 파마슈티컬스 인코퍼레이티드 Limk2 억제제, 그를 포함하는 조성물 및 그의 사용 방법
KR20120131161A (ko) * 2010-01-25 2012-12-04 씨에이치디아이 파운데이션, 인코포레이티드 특정 키뉴레닌-3-모노옥시게나제 억제제, 그의 제약 조성물 및 사용 방법
JP2013107824A (ja) * 2010-03-17 2013-06-06 Dainippon Sumitomo Pharma Co Ltd 新規単環ピリミジン誘導体
WO2012078687A1 (en) * 2010-12-06 2012-06-14 Confluence Life Sciences, Inc. Substituted pyrimidine urea compounds
KR20140072037A (ko) 2011-08-30 2014-06-12 씨에이치디아이 파운데이션, 인코포레이티드 키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법
EA032526B1 (ru) 2011-08-30 2019-06-28 Схди Фаундейшн, Инк. Применение ингибитора кинуренин-3-монооксигеназы для лечения заболеваний и состояний, опосредованных активностью кинуренин-3-монооксигеназы
US9532972B2 (en) * 2012-02-07 2017-01-03 University Of Central Florida Research Foundation, Inc. Increasing taxane sensitivity in cancer cells
US10105351B2 (en) 2012-03-14 2018-10-23 University Of Central Florida Research Foundation, Inc. Neurofibromatoses therapeutic agents and screening for same
WO2015025172A1 (en) * 2013-08-22 2015-02-26 Mark David Charles 5-aryl-thiazol-2-yl-amine compounds and their therapeutic use
PT3080103T (pt) * 2013-12-11 2018-07-23 Sunesis Pharmaceuticals Inc Compostos de biaril úteis no tratamento de doenças humanas em oncologia, neurologia e imunologia
KR20170026633A (ko) 2014-07-17 2017-03-08 씨에이치디아이 파운데이션, 인코포레이티드 Hiv-관련 장애의 치료 방법 및 치료용 조성물
US10292122B2 (en) * 2014-10-11 2019-05-14 Telefonaktiebolaget Lm Ericsson (Publ) Method and access point for maintaining synchronization among access points in radio access network
JP6616244B2 (ja) * 2015-05-29 2019-12-04 北興化学工業株式会社 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法
PL3319959T3 (pl) 2015-07-06 2022-02-14 Alkermes, Inc. Hetero-haloinhibitory deacetylazy histonowej
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
CA3030581C (en) * 2016-07-18 2021-05-25 National Institute Of Biological Sciences, Beijing Apoptosis inhibitors
JP2019532944A (ja) 2016-09-23 2019-11-14 セルイプセ Limk介在性疾患における、limキナーゼ阻害剤、医薬組成物および使用方法
CN106727536B (zh) * 2016-11-30 2019-05-31 东南大学 LIM激酶抑制剂LIMKi3在制备治疗疼痛药物中的应用
AU2018207402B2 (en) 2017-01-11 2023-09-28 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US11040947B2 (en) 2017-03-22 2021-06-22 The Research Foundation For The State University Of New York Substituted quinazolines as matrix metalloproteinase-9 hemopexin domain inhibitors
ES2914355T3 (es) 2017-08-07 2022-06-09 Alkermes Inc Inhibidores bicíclicos de la histona desacetilasa
CN111601593B (zh) 2017-10-05 2022-04-15 弗尔康医疗公司 P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3082855A1 (en) 2017-11-21 2019-05-31 Bayer Aktiengesellschaft 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists
EP3740484B1 (de) 2018-01-15 2024-09-11 Aucentra Therapeutics Pty Ltd 5-(pyrimidin-4-yl)thiazol-2-yl-harnstoffderivate als therapeutika
CN117003730A (zh) * 2022-04-29 2023-11-07 德明药泰生物技术(深圳)有限公司 取代嘧啶酰肼类化合物及其制备方法和应用
CN117624135A (zh) * 2022-08-19 2024-03-01 德明药泰生物技术(深圳)有限公司 2-氮取代嘧啶类化合物及其制备方法和应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2201083A1 (en) * 1972-09-28 1974-04-26 Ferlux 6-Phenyl pyrimidine-4-carboxylic acids - analgesics, vasodilators, cardiac stimulants and respiratory analeptics
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA1288433C (en) * 1986-12-03 1991-09-03 Tsuguhiro Katoh Pyridinylpyrimidine derivatives, method for production thereof and a fungicide containing them as the active ingredient
DE3922735A1 (de) * 1989-07-11 1991-01-24 Hoechst Ag Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
DE3940476A1 (de) * 1989-12-07 1991-06-13 Bayer Ag Pyridinylpyrimidin-derivate
US5022915A (en) * 1990-03-01 1991-06-11 Ici Americas Inc. Substituted 2,4-diarylpyrimidines and their use as herbicides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
DE69624437T2 (de) * 1995-04-13 2003-08-07 Taiho Pharmaceutical Co. Ltd., Tokio/Tokyo 4,6-diarylpyrimidin-derivate und deren salze
US5658903A (en) 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
ES2205167T3 (es) 1996-01-11 2004-05-01 Smithkline Beecham Corporation Nuevos compuestos de imidazol sustituidos.
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5945418A (en) 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
KR20010012808A (ko) 1997-05-22 2001-02-26 윌리암스 로저 에이 p38 키나아제로서 4-아릴-3(5)-헤테로아릴 치환 피라졸
US6087496A (en) 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
AU8381098A (en) 1997-07-02 1999-01-25 Smithkline Beecham Corporation Novel cycloalkyl substituted imidazoles
US6130235A (en) 1998-05-22 2000-10-10 Scios Inc. Compounds and methods to treat cardiac failure and other disorders
CA2342251A1 (en) 1998-08-28 2000-03-09 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
AR023659A1 (es) * 1998-09-18 2002-09-04 Vertex Pharma Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
WO2000034244A1 (en) 1998-12-04 2000-06-15 Bristol-Myers Squibb Company 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
JP2001089452A (ja) 1999-09-22 2001-04-03 Sankyo Co Ltd ピリミジン誘導体
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
JP2003513977A (ja) 1999-11-10 2003-04-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換2−アリール−3−(ヘテロアリール)−イミダゾ[1,2−α]ピリミジン類および関連薬剤組成物および方法
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
JP2001199982A (ja) * 2000-01-14 2001-07-24 Dainippon Pharmaceut Co Ltd 6−ヘテロアリールピリミジン誘導体及びそれを含有する医薬組成物
AR029489A1 (es) * 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
NZ521068A (en) * 2000-03-29 2005-04-29 Cyclacel Ltd 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
PE20020451A1 (es) 2000-09-15 2002-06-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de cinasa proteina
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
ES2254611T3 (es) 2001-05-11 2006-06-16 Pfizer Products Inc. Derivados de tiazol.
EP1760082A1 (de) * 2001-09-28 2007-03-07 Cyclacel Limited N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-Phenylamine als antiproliferative Verbindungen
US6916813B2 (en) * 2001-12-10 2005-07-12 Bristol-Myers Squibb Co. (1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase
JP2003206230A (ja) 2002-01-10 2003-07-22 Yamanouchi Pharmaceut Co Ltd シアノヘテロ環誘導体又はその塩
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
GB0226582D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Anti-viral compounds
DE602004028907D1 (de) * 2003-02-06 2010-10-14 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
WO2004080979A1 (en) * 2003-03-14 2004-09-23 Lg Life Sciences Ltd. Novel 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl ketone derivatives
US20060293339A1 (en) 2003-03-24 2006-12-28 Chakravarty Prasun K Biaryl substituted 6-membered heterocycles as sodium channel blockers
EP1644338A1 (de) * 2003-04-01 2006-04-12 Aponetics AG 2,4,6-trisubstituierte pyrimidinderivate, die sich für die behandlung von neoplastischen krankheiten und autoimmunkrankheiten eignen
TW200519106A (en) * 2003-05-02 2005-06-16 Novartis Ag Organic compounds
WO2005007648A2 (en) * 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
GB0403155D0 (en) * 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
US20050282824A1 (en) * 2004-05-07 2005-12-22 Xiaobing Li Substituted pyrimidines as inhibitors of bacterial type III protein secretion systems
WO2006071538A2 (en) * 2004-12-13 2006-07-06 Neurogen Corporation Substituted biaryl analogues

Also Published As

Publication number Publication date
DE602006011434D1 (de) 2010-02-11
EP1848714A2 (de) 2007-10-31
ES2336025T3 (es) 2010-04-07
JP2008530012A (ja) 2008-08-07
US20100029649A1 (en) 2010-02-04
EP1848714B1 (de) 2009-12-30
US7923556B2 (en) 2011-04-12
WO2006084017A2 (en) 2006-08-10
US20060178388A1 (en) 2006-08-10
JP4906738B2 (ja) 2012-03-28
WO2006084017A3 (en) 2006-12-14

Similar Documents

Publication Publication Date Title
ATE453639T1 (de) Phenylsubstituierte pyrimidinverbindungen zur verwendung als kinasehemmer
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
ATE433981T1 (de) Heterocyclische verbindungen
ATE508747T1 (de) C-kit kinase-hemmer
GEP20074148B (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
SE0202463D0 (sv) Novel compounds
MY153727A (en) Pyridazinone derivatives
SG154432A1 (en) Quinazolinedione derivatives as parp inhibitors
TW200610531A (en) Phthalazine derivatives as PARP inhibitors
ATE406351T1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
DK1070056T3 (da) Phthalazinon-PDE III/IV-inhibitorer
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
MX2009012709A (es) Derivados de arileter-piridazinona.
IL181271A0 (en) Triazolophthalazine derivatives and pharmaceutical compositions containing the same
TW200716529A (en) New compounds II
MX2007015742A (es) Aminopirimidinas como moduladores de cinasa.
TW200716599A (en) Alkylquinoline and alkylquinazoline kinase modulators
UA94570C2 (en) Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
SE0403171D0 (sv) New compounds
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
MX2008001778A (es) Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.
DK1147088T3 (da) 6-arylphenanthridiner med PDE-IV-inhiberende aktivitet
ATE413392T1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties